Picture loading failed.

Pre-made Acasunlimab benchmark antibody (Bispecific mAb, anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-007-1mg 1mg Inquiry
GMP-Bios-ab-007-10mg 10mg Inquiry
GMP-Bios-ab-007-100mg 100mg Inquiry
GMP-Bios-ab-007-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-CD274/PD-L1;TNFRSF9/CD137 Antibod: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 therapeutic antibody
INN Name Acasunlimab
TargetPD-L1;CD137
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda;Kappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesGenmab;BioNTech
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna